GlobeNewswire

Orion Biotechnology Canada Announces Partnership with Nanjing University

Del

OTTAWA, March 28, 2018 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd, a developer of novel medical treatments for chronic illness and life-threatening diseases, today announced a strategic partnership with the Center for Public Health Research (CPHR) and the State Key Laboratory of Analytical Chemistry (SKLAC) of Nanjing University. The partnership will focus on supporting the development of Orion's China sourced biopharmaceutical solutions, including the company's unique multipurpose microbicide candidate (OB-001) - a non-antiretroviral microbicide designed to be a contraceptive which also prevents the transmission of HIV.

"We are delighted to work with Nanjing University, one of the top academic centers in China," said Mark Groper, President & CEO of Orion. "Orion is committed to sourcing and developing solutions for the China market. Our partnership with Nanjing University is an important step forward for our China program and we look forward to developing a strong and mutually beneficial relationship." Orion has established a series of collaborations with leading universities and research institutes around the globe to facilitate more rapid identification and development of novel treatments for emerging health issues.

Nanjing University's SKLAC and CPHR will collaborate with Orion in conducting research and development, pre-clinical testing and IND-enabling studies. Dr. Allen Wu, Professor and Associate Director of the SKLAC, expressed optimism and excitement about this collaboration. "Academic and industry collaborations help tackle the gap between fundamental scientific discovery and commercial application. We are pleased to be working closely with Orion, a very promising biotechnology company with excellent management and a strong R&D team. Our collaboration will focus initially on Orion's unique HIV prevention solution - a large and growing unmet need medical need in China."

About Orion Biotechnology Canada, Ltd.
Orion Biotechnology Canada Ltd, is a privately held pharmaceutical company founded on the vision of radically improving the health of the global population through successful treatment and prevention of the most serious chronic illnesses and life-threatening diseases. Since 2011, Orion has been developing a robust pipeline of potential products based on novel formulations discovered in different parts of the world. Our close ties to diverse institutions and experts around the globe continue to stimulate the rapid discovery of promising new treatments. With operations in North America, Europe and Asia, Orion brings together innovative technologies from some of the world's leading research institutions such as the Mintaka Research Foundation and the Center for Public Health Research at Nanjing University. Learn more at www.orionbiotechnology.com.

Forward-Looking Statements
This press release contains forward-looking information, which reflects Orion's current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Orion's control, that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, Orion assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact: Ross MacLeod
Orion Biotechnology 
Canada Ltd
Phone: +1.343.291.1032
info@orionbiotechnology.com 

343 Preston Street
11th Floor, Ottawa, Ontario
www.orionbiotechnology.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Orion Biotechnology Canada Ltd via Globenewswire

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

ISSI HyperFlash™ memory has successfully been designed into the NXP i.MX RT106A MCU-based solution for AVS (Alexa Voice Service)19.3.2019 21:30:00 CETPressemelding

MILPITAS, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Integrated Silicon Solution, Inc. a leader in advanced memory solutions, today announced the adoption of HyperFlash™ memory IS26KL256S-DABLI00 (256Mb 3.3V BGA package) with NXP’s i.MX RT106A MCU based solution for AVS (Alexa Voice Service). The Alexa Voice Service (AVS) is a virtual assistant developed by Amazon that provides cloud-based automatic speech recognition (ASR) and natural language understanding (NLU) to provide information, media playback, communication and smart device control capabilities to consumers. HyperFlash™ memory based on the HyperBus™ technology dramatically improves memory performance while reducing pin count and board space, essential for NXP’s implementation to save BOM cost without compromising performance to do XIP (execute-in-place) operations. “NXP is an important partner for us. We are very glad that NXP adopted our HyperFlash™ solution. HyperFlash™ fits nicely in the application to meet the increasingl

NLS Pharmaceutics Announces the Completion of the Merger between NLS Pharma Ltd., NLS-1 Pharma Ltd. and NLS-0 Pharma, Unifying the Global Operations and Development of Nolazol®19.3.2019 21:05:00 CETPressemelding

The combined company was named NLS Pharmaceutics Ltd (NLS) STANS, Switzerland, March 19, 2019 (GLOBE NEWSWIRE) -- NLS Pharmaceutics Ltd (NLS), a Swiss biotech firm focusing on the development of novel treatments for Attention-Deficit/Hyperactivity Disorder (ADHD) and other cognitive disorders and impairments, today announced the closing of the merger of NLS Pharma Ltd., NLS-1 Pharma Ltd. and NLS-0 Pharma, effective immediately. The combined company was named “NLS Pharmaceutics Ltd.” The sideways merger brings together the global operations and assets of the three companies in order to streamline the development of Nolazol®, a controlled release formulation of mazindol that is currently being developed as a non-amphetamine DEA schedule C-4 treatment option for ADHD and narcolepsy, as well as a promising pipeline of early to late-stage compounds focusing on ADHD, sleep disorder and other rare diseases. Leading the combined company as Chief Executive Officer is Alex Zwyer, who served as c

INVNT Recognised for Xero and TEDxSydney Work at The Event Marketing Awards 201919.3.2019 14:30:00 CETPressemelding

HONG KONG, March 19, 2019 (GLOBE NEWSWIRE) -- INVNT, the global live brand storytelling agency™, in partnership with Xero has received the Best Corporate Event Gold Award at the prestigious Event Marketing Awards 2019 organised by Campaign Asia-Pacific and CEI, for its production, management and design of Xerocon Brisbane 2018 – Australasia’s largest technology conference for the accounting industry. During the ceremony, which was held at the Eaton Club in Hong Kong on Tuesday evening local time, INVNT was also recognised with the Best Sustainability Bronze Award alongside client TEDxSydney, for the production of the not-for-profit organisation’s flagship event in 2018, which was themed around the concept of HumanKind and saw the agency devise and implement a series of environmentally friendly initiatives. Now in their fourth year, the Event Marketing Awards organised by Campaign Asia-Pacific and CEI recognise best practice in the creation, planning, production and management of innova

Crocus Technology Unveils its 2nd Generation TMR Linear Sensor with Unparalleled Temperature Stability19.3.2019 13:00:00 CETPressemelding

The CT100 is a unique TMR magnetic sensor with industry-leading performance SANTA CLARA, Calif., March 19, 2019 (GLOBE NEWSWIRE) -- Crocus Technology Inc., a leading supplier of disruptive Tunnel Magneto-Resistance (TMR) sensors, today announces the CT100 device, an advanced, high-performance linear (1D) magnetic sensor based on Crocus’ patented and unique TMR-based technology. The CT100 has best-in-class performance across a wide temperature range coupled with an extremely low linearity error, low hysteresis, and low noise which enables it to address many consumer, industrial and automotive applications and markets. The CT100 outperforms competitors’ xMR or Hall-based linear magnetic sensor technology available today in terms of performance, deviation over temperature, current consumption, and overall robustness. The CT100 does not require any expensive flux guides or concentrators, chopping circuits or set/reset pulses and operates over a wide magnetic field range. Crocus’s revolutio

Despite Brexit Uncertainty, Business Schools in UK Continue to See Strong International Demand19.3.2019 09:00:00 CETPressemelding

Majority of Candidates Say Brexit has No Impact on Decision to Study in the United Kingdom RESTON, Va., March 19, 2019 (GLOBE NEWSWIRE) -- In response to the initial Brexit vote in June 2016, the Graduate Management Admission Council™ (GMAC™) has been tracking Graduate Management Admission Test™ (GMAT™) examinee interest in studying in the UK. This has included periodic surveys of non-U.K. citizens who sent a GMAT score report to a UK business school program, as an indication of where they are interested in studying. In the immediate aftermath of the vote, it was unclear what the impact would be on the international flow of students to UK programs, which are heavily reliant on enrollees from other countries. Brexit, it’s been feared, could restrict or complicate the student visa process and dampen international candidates’ postgraduation job prospects in the UK, both because of possible changes to work visa policies and jobs leaving the UK. However, the most recent survey findings, fro

General Electric Company: Doc re. GE files DEFA14A19.3.2019 08:00:00 CETPressemelding

FAIRFIELD, Conn., March 19, 2019 (GLOBE NEWSWIRE) -- Company ISIN Symbol Headline General Electric Company US3696041033 London: GEC | Paris: GNE Doc re: GE files DEFA14A March 18, 2019 On March 18, 2019, General Electric Company (the "Company") filed a DEFA14A (Definitive Additional Materials) with the U.S. Securities and Exchange Commission ("SEC"), which has been submitted to the U.K. National Storage Mechanism and will be available shortly for inspection at http://www.morningstar.co.uk/uk/NSM. It is also available on the SEC's website at http://www.sec.gov and on the Company's website at https://www.ge.com/investor-relations/events-reports. CONTACT: GE Jennifer Erickson +001 646 682 5620 jennifer.erickson@ge.com This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this informatio